# Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections

> **NCT03445195** · PHASE2 · COMPLETED · sponsor: **Entasis Therapeutics** · enrollment: 80 (actual)

## Conditions studied

- Complicated Urinary Tract Infection
- Acute Pyelonephritis

## Interventions

- **DRUG:** Sulbactam-ETX2514
- **DRUG:** Placebo
- **DRUG:** Imipenem-cilastatin

## Key facts

- **NCT ID:** NCT03445195
- **Lead sponsor:** Entasis Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-17
- **Primary completion:** 2018-05-17
- **Final completion:** 2018-05-17
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03445195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03445195, "Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03445195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*